Immune cells harvested from tumors could fight advanced colorectal cancer

NCT ID NCT06819280

Recruiting now Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new therapy called GT307, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack advanced colorectal cancer. The trial enrolls 18 adults whose cancer has worsened after first-line chemotherapy. The main goals are to check safety and see if the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GT307 (autologous tumor-infiltrating lymphocytes)
What this could lead to: If successful, this could point toward a new treatment option for advanced colorectal cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is a very early, small study (18 people) focused mainly on safety. The therapy may not shrink tumors, and side effects could be serious. It is not yet proven to work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT

Contacts and locations

Locations

Shanghai Jiaotong University School of Medcine, Renji Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.